Clinical Trial Update: A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating 48 vs 96 weeks of Pegasys (peginterferon alfa-2a) with or without entecavir in chronic hepatitis B was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Baraclude (entecavir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: WITHDRAWN